Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study.

Andréasson M, Brodin L, Laffita-Mesa JM, Svenningsson P.

J Parkinsons Dis. 2017;7(4):619-628. doi: 10.3233/JPD-171127.

PMID:
28759974
2.

Polyneuropathy in levodopa-treated Parkinson's patients.

Szadejko K, Dziewiatowski K, Szabat K, Robowski P, Schinwelski M, Sitek E, Sławek J.

J Neurol Sci. 2016 Dec 15;371:36-41. doi: 10.1016/j.jns.2016.09.061. Epub 2016 Oct 2.

PMID:
27871444
3.

Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.

Białecka M, Kurzawski M, Roszmann A, Robowski P, Sitek EJ, Honczarenko K, Gorzkowska A, Budrewicz S, Mak M, Jarosz M, Gołąb-Janowska M, Koziorowska-Gawron E, Droździk M, Sławek J.

Pharmacogenet Genomics. 2012 Oct;22(10):716-24. doi: 10.1097/FPC.0b013e32835693f7.

PMID:
22890010
4.

Catechol-O-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson's disease.

Zhang Y, Feng S, Nie K, Zhao X, Gan R, Wang L, Zhao J, Tang H, Gao L, Zhu R, Wang L, Zhang Y.

J Neurol Sci. 2016 Oct 15;369:347-353. doi: 10.1016/j.jns.2016.08.063. Epub 2016 Aug 31.

PMID:
27653922
5.

Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.

Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D; Parkgait-II Study Group.

Brain. 2015 May;138(Pt 5):1271-83. doi: 10.1093/brain/awv063. Epub 2015 Mar 23.

6.

Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.

Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, Lamberti SV, Fraddosio A, de Mari M, Livrea P.

Clin Chem Lab Med. 2005;43(10):1107-10.

PMID:
16197306
7.

Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.

Hu XW, Qin SM, Li D, Hu LF, Liu CF.

Acta Neurol Scand. 2013 Aug;128(2):73-82. doi: 10.1111/ane.12106. Epub 2013 Feb 21. Review.

PMID:
23432663
8.

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.

Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, Livrea P.

Mov Disord. 2005 Jan;20(1):69-72.

PMID:
15390046
9.

The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.

Torkaman-Boutorabi A, Shahidi GA, Choopani S, Rezvani M, Pourkosary K, Golkar M, Zarrindast MR.

Acta Neurobiol Exp (Wars). 2012;72(3):272-82.

10.

The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.

Białecka M, Droździk M, Kłodowska-Duda G, Honczarenko K, Gawrońska-Szklarz B, Opala G, Stankiewicz J.

Acta Neurol Scand. 2004 Oct;110(4):260-6.

PMID:
15355491
11.

Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.

De Bonis ML, Tessitore A, Pellecchia MT, Longo K, Salvatore A, Russo A, Ingrosso D, Zappia V, Barone P, Galletti P, Tedeschi G.

Neurosci Lett. 2010 Jan 14;468(3):287-91. doi: 10.1016/j.neulet.2009.11.014. Epub 2009 Nov 10.

PMID:
19909787
12.

Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease.

Tan EK, Cheah SY, Fook-Chong S, Yew K, Chandran VR, Lum SY, Yi Z.

Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4.

PMID:
15965967
13.

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.

Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M.

Pharmacogenet Genomics. 2008 Sep;18(9):815-21. doi: 10.1097/FPC.0b013e328306c2f2.

PMID:
18698234
14.

Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.

Nevrly M, Kanovsky P, Vranova H, Langova K, Hlustik P.

Neurol Sci. 2010 Oct;31(5):565-9. doi: 10.1007/s10072-010-0262-0. Epub 2010 May 13.

PMID:
20464572
15.

Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.

Zoccolella S, Lamberti P, Armenise E, de Mari M, Lamberti SV, Mastronardi R, Fraddosio A, Iliceto G, Livrea P.

Parkinsonism Relat Disord. 2005 Mar;11(2):131-3. Epub 2004 Dec 20.

PMID:
15734674
16.

Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.

Camicioli RM, Bouchard TP, Somerville MJ.

Mov Disord. 2009 Jan 30;24(2):176-82. doi: 10.1002/mds.22227.

PMID:
18951534
17.

Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson's disease.

Wu H, Dong F, Wang Y, Xiao Q, Yang Q, Zhao J, Quinn TJ, Chen SD, Liu J.

Parkinsonism Relat Disord. 2014 Oct;20(10):1094-6. doi: 10.1016/j.parkreldis.2014.07.011. Epub 2014 Jul 27.

PMID:
25108642
18.

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.

Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M.

Ann Neurol. 2011 Jan;69(1):111-8. doi: 10.1002/ana.22155.

PMID:
21280081
19.

Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.

Contin M, Martinelli P, Mochi M, Riva R, Albani F, Baruzzi A.

Mov Disord. 2005 Jun;20(6):734-9.

PMID:
15747357
20.

Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment?

Zoccolella S, dell'Aquila C, Specchio LM, Logroscino G, Lamberti P.

Curr Med Chem. 2010;17(3):213-21. Review.

PMID:
20214564

Supplemental Content

Support Center